Showing results (151-160 of 682) with videos related to

Sort By:
Pageof 69
Clinical Lymphoma, Myeloma & Leukemia|November 6, 2012
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibodyPaolo Strati, Jorge Cortes, Stefan Faderl, et al.
Physiological Genomics|May 15, 2014
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AMLPankit Vachhani, Prithviraj Bose, Mohamed Rahmani, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 1, 2016
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesPrithviraj Bose, Varsha V Gandhi, Michael J Keating
Leukemia Research|September 18, 2007
Thrombosis of the corpora cavernosa complicating lenalidomide therapy of myelofibrosisFuad A El Rassi, Constantine S Tam, John Carwile, et al.
Expert Opinion on Pharmacotherapy|April 28, 2017
Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemiaAbdallah Abou Zahr, Prithviraj Bose, Michael J Keating
Expert Review of Clinical Pharmacology|April 8, 2026
A pharmacological profile of pacritinib for the treatment of myelofibrosisHannah Goulart, Lucia Masarova, Naveen Pemmaraju, et al.
Hematological Oncology|August 15, 2018
Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosisSrdan Verstovsek, Swamy Yeleswaram, Kevin Hou, et al.
Leukemia & Lymphoma|January 3, 2013
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosisAlfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2013
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, et al.
Cancer|July 27, 2007
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophiliaMatko Kalac, Alfonso Quintás-Cardama, Radovan Vrhovac, et al.
Pageof 69